Capital Advisors Ltd’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $167K | Sell |
1,319
-112
| -8% | -$14.8K | 0.02% | 323 |
|
|
2026
Q1 | $199K | Buy |
1,431
+83
| +6% | +$11.6K | 0.02% | 293 |
|
|
2025
Q4 | $165K | Hold |
1,348
| – | – | 0.02% | 302 |
|
|
2025
Q3 | $150K | Hold |
1,348
| – | – | 0.02% | 315 |
|
|
2025
Q2 | $149K | Buy |
1,348
+72
| +6% | +$7.66K | 0.02% | 302 |
|
|
2025
Q1 | $143K | Sell |
1,276
-1
| -0.1% | -$103 | 0.02% | 310 |
|
|
2024
Q4 | $118K | Buy |
1,277
+26
| +2% | +$2.34K | 0.01% | 324 |
|
|
2024
Q3 | $105K | Sell |
1,251
-3
| -0.2% | -$229 | 0.01% | 336 |
|
|
2024
Q2 | $86K | Sell |
1,254
-166
| -12% | -$11.1K | 0.01% | 352 |
|
|
2024
Q1 | $104K | Buy |
1,420
+162
| +13% | +$12.5K | 0.01% | 334 |
|
|
2023
Q4 | $102K | Buy |
1,258
+42
| +3% | +$3.27K | 0.01% | 331 |
|
|
2023
Q3 | $91K | Buy |
1,216
+53
| +5% | +$4.08K | 0.01% | 337 |
|
|
2023
Q2 | $90K | Buy |
1,163
+639
| +122% | +$51K | 0.01% | 350 |
|
|
2023
Q1 | $43K | Sell |
524
-744
| -59% | -$61.6K | 0.01% | 388 |
|
|
2022
Q4 | $49K | Buy |
1,268
+661
| +109% | +$52.3K | 0.01% | 374 |
|
|
2022
Q3 | $37K | Buy |
607
+138
| +29% | +$8.7K | 0.01% | 390 |
|
|
2022
Q2 | $29K | Buy |
469
+17
| +4% | +$1.05K | 0.01% | 402 |
|
|
2022
Q1 | $27K | Buy |
452
+6
| +1% | +$384 | ﹤0.01% | 421 |
|
|
2021
Q4 | $32K | Buy |
446
+250
| +128% | +$17.2K | 0.01% | 392 |
|
|
2021
Q3 | $14K | Hold |
196
| – | – | ﹤0.01% | 404 |
|
|
2021
Q2 | $13K | Hold |
196
| – | – | ﹤0.01% | 393 |
|
|
2021
Q1 | $13K | Hold |
196
| – | – | ﹤0.01% | 384 |
|
|
2020
Q4 | $11K | Hold |
196
| – | – | ﹤0.01% | 376 |
|
|
2020
Q3 | $12K | Hold |
196
| – | – | ﹤0.01% | 373 |
|
|
2020
Q2 | $15K | Hold |
196
| – | – | ﹤0.01% | 344 |
|
|
2020
Q1 | $15K | Sell |
196
-434
| -69% | -$30K | ﹤0.01% | 334 |
|
|
2019
Q4 | $41K | Hold |
630
| – | – | 0.01% | 270 |
|
|
2019
Q3 | $40K | Sell |
630
-166
| -21% | -$10.9K | 0.01% | 269 |
|
|
2019
Q2 | $54K | Buy |
796
+166
| +26% | +$10.9K | 0.02% | 278 |
|
|
2019
Q1 | $41K | Hold |
630
| – | – | 0.01% | 303 |
|
|
2018
Q4 | $39K | Hold |
630
| – | – | 0.01% | 305 |
|
|
2018
Q3 | $49K | Hold |
630
| – | – | 0.01% | 307 |
|
|
2018
Q2 | $45K | Hold |
630
| – | – | 0.01% | 241 |
|
|
2018
Q1 | $47K | Hold |
630
| – | – | 0.02% | 229 |
|
|
2017
Q4 | $45K | Hold |
630
| – | – | 0.01% | 229 |
|
|
2017
Q3 | $51K | Hold |
630
| – | – | 0.02% | 221 |
|
|
2017
Q2 | $45K | Buy |
+630
| New | +$41.9K | 0.02% | 226 |
|
Other funds holding GILD
Capital Advisors Ltd's GILD Position: Q2 2026 in Review
Capital Advisors Ltd reduced its Gilead Sciences (GILD) stake by 7.8% in Q2 2026, selling an estimated $14.8K and leaving 1,319 shares worth $167K. The position accounts for 0.02% of the portfolio, ranked #323.
Capital Advisors Ltd first reported a position in GILD in Q2 2017 and has held it in 37 quarters since. The position peaked at $199K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Capital Advisors Ltd held 1,319 shares of Gilead Sciences worth $167K as of Q2 2026.
- Capital Advisors Ltd sold 112 Gilead Sciences shares in Q2 2026, an estimated $14.8K.
- Gilead Sciences made up 0.02% of Capital Advisors Ltd's portfolio in Q2 2026, its #323 holding.
- Capital Advisors Ltd first reported a position in Gilead Sciences in Q2 2017 and has held it in 37 quarters since.
- Capital Advisors Ltd's Gilead Sciences position peaked at $199K in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.